Related Experiment Videos
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss
V Michael Holers1, Guillermina Girardi, Lian Mo
1Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
The Journal of Experimental Medicine
|January 24, 2002
Summary
Antiphospholipid syndrome (APS) causes pregnancy loss by activating complement. Blocking complement prevents fetal loss in APS, demonstrating its critical role in this condition.
Area of Science:
- Obstetrics and Gynecology
- Immunology
- Hematology
Background:
- Antiphospholipid syndrome (APS) is linked to recurrent fetal loss, vascular thrombosis, and thrombocytopenia.
- The exact mechanisms causing fetal loss and placental injury in APS remain unclear.
- Uncontrolled placental complement activation is implicated in fetal death during pregnancy.
Purpose of the Study:
- To investigate the role of complement activation in antiphospholipid antibody-mediated fetal loss and growth retardation.
- To test the hypothesis that antiphospholipid antibodies activate complement in the placenta, leading to fetal complications.
Main Methods:
- Utilized a murine model of APS involving pregnant mice injected with human IgG containing antiphospholipid antibodies.
- Administered a complement cascade inhibitor (Crry-Ig) to assess its effect on fetal outcomes.
- Examined fetal injury in mice deficient in complement C3.
Main Results:
- Inhibition of the complement cascade in vivo prevented fetal loss and growth retardation in the APS model.
- Mice lacking complement C3 showed resistance to antiphospholipid antibody-induced fetal injury.
- Complement activation was identified as a necessary in vivo mechanism for antiphospholipid antibody-induced fetal complications.
Conclusions:
- Complement activation is a critical mediator of placental injury and fetal loss in antiphospholipid syndrome.
- Targeting the complement cascade represents a potential therapeutic strategy for managing APS-related pregnancy complications.